This preprint is under consideration at Scientific Reports. A preprint is a preliminary version of a manuscript that has not completed peer review at a journal. Research Square does not conduct peer review prior to posting preprints. The posting of a preprint on this server should not be interpreted as an endorsement of its validity or suitability for dissemination as established information or for guiding clinical practice.
Learn more about In Review
A new preprint design is coming!
We have improved readability, clarity, accessibility, and opportunities for engagement.
Research Article
Mark Fidock
AstraZeneca (United Kingdom)
Corresponding Author
License:
This work is licensed under a CC BY 4.0 License. Read Full License
Regular PCR testing of nasopharyngeal swabs from symptomatic individuals for SARS-CoV-2 virus has become the established method by which health services are managing the COVID-19 pandemic. Businesses such as AstraZeneca have also prioritised voluntary asymptomatic testing to keep workplaces safe and maintain supply of essential medicines to patients. We describe the development of an internal automated SARS-CoV-2 testing programme including the transformative introduction of saliva as an alternative sample type.
Keywords
PCR testing, SARS-CoV-2 virus, saliva sample
Figure 1
Figure 2
Competing interest reported. All authors are employees of AstraZeneca and have financial interests in the company.
Loading...
Badges
Prescreen
This manuscript passed our Prescreen assessment
Complete author information
Appropriate declaration statements
Potential risks to human health
Prescreen
Peer Review Timeline
CURRENT STATUS: Under Review
Version 2
Posted 18 Mar, 2021
No community comments so far
Editorial decision: Major revision
On 27 Apr, 2021
Reviews received
Received 12 Apr, 2021
Reviewers agreed
On 05 Apr, 2021
Reviewers invited
Invitations sent on 26 Mar, 2021
Editor assigned
On 26 Mar, 2021
Editor invited
On 15 Mar, 2021
Submission checks complete
On 15 Mar, 2021
First submitted
On 05 Mar, 2021
Archived Versions
Posted to Research Square
No comments provided
Metrics
Comments: 0
PDF Downloads: ...
HTML Views: ...
Learn more about our company.
A new preprint design is coming!
We have improved readability, clarity, accessibility, and opportunities for engagement.
This preprint is under consideration at Scientific Reports. A preprint is a preliminary version of a manuscript that has not completed peer review at a journal. Research Square does not conduct peer review prior to posting preprints. The posting of a preprint on this server should not be interpreted as an endorsement of its validity or suitability for dissemination as established information or for guiding clinical practice.
Learn more about In Review
Research Article
Mark Fidock
AstraZeneca (United Kingdom)
Corresponding Author
Badges
Prescreen
This manuscript passed our Prescreen assessment
Complete author information
Appropriate declaration statements
Potential risks to human health
Prescreen
Peer Review Timeline
CURRENT STATUS: Under Review
Version 2
Posted 18 Mar, 2021
No community comments so far
Editorial decision: Major revision
On 27 Apr, 2021
Reviews received
Received 12 Apr, 2021
Reviewers agreed
On 05 Apr, 2021
Reviewers invited
Invitations sent on 26 Mar, 2021
Editor assigned
On 26 Mar, 2021
Editor invited
On 15 Mar, 2021
Submission checks complete
On 15 Mar, 2021
First submitted
On 05 Mar, 2021
Metrics
Comments: 0
PDF Downloads: ...
HTML Views: ...
License:
This work is licensed under a CC BY 4.0 License. Read Full License
Regular PCR testing of nasopharyngeal swabs from symptomatic individuals for SARS-CoV-2 virus has become the established method by which health services are managing the COVID-19 pandemic. Businesses such as AstraZeneca have also prioritised voluntary asymptomatic testing to keep workplaces safe and maintain supply of essential medicines to patients. We describe the development of an internal automated SARS-CoV-2 testing programme including the transformative introduction of saliva as an alternative sample type.
Figure 1
Figure 2
Competing interest reported. All authors are employees of AstraZeneca and have financial interests in the company.
Loading...